Choreo LLC Makes New $690,000 Investment in BioNTech SE (NASDAQ:BNTX)

Choreo LLC acquired a new stake in shares of BioNTech SE (NASDAQ:BNTX) in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 8,755 shares of the company’s stock, valued at approximately $690,000.

Other institutional investors have also recently made changes to their positions in the company. Jump Financial LLC purchased a new stake in shares of BioNTech during the 4th quarter worth approximately $268,000. Quadrant Capital Group LLC purchased a new stake in shares of BioNTech during the 4th quarter worth approximately $85,000. Dynamic Technology Lab Private Ltd raised its holdings in shares of BioNTech by 2.5% during the 4th quarter. Dynamic Technology Lab Private Ltd now owns 4,666 shares of the company’s stock worth $492,000 after acquiring an additional 116 shares in the last quarter. PNC Financial Services Group Inc. raised its holdings in shares of BioNTech by 207.5% during the 4th quarter. PNC Financial Services Group Inc. now owns 2,583 shares of the company’s stock worth $273,000 after acquiring an additional 1,743 shares in the last quarter. Finally, Wells Fargo & Company MN raised its holdings in shares of BioNTech by 6.8% during the 4th quarter. Wells Fargo & Company MN now owns 82,171 shares of the company’s stock worth $8,672,000 after acquiring an additional 5,227 shares in the last quarter. Hedge funds and other institutional investors own 15.52% of the company’s stock.

BioNTech Stock Performance

BNTX stock opened at $123.40 on Friday. The company has a quick ratio of 7.40, a current ratio of 7.54 and a debt-to-equity ratio of 0.01. The business’s fifty day simple moving average is $87.28 and its two-hundred day simple moving average is $89.67. BioNTech SE has a twelve month low of $76.53 and a twelve month high of $125.41. The firm has a market cap of $29.34 billion, a price-to-earnings ratio of 246.80 and a beta of 0.23.

BioNTech (NASDAQ:BNTX) last released its earnings results on Monday, August 5th. The company reported ($3.36) earnings per share for the quarter, missing analysts’ consensus estimates of ($2.02) by ($1.34). BioNTech had a negative return on equity of 2.54% and a negative net margin of 18.69%. The business had revenue of $128.70 million during the quarter, compared to analysts’ expectations of $134.98 million. During the same quarter in the previous year, the business earned ($0.86) EPS. The business’s revenue for the quarter was down 23.3% on a year-over-year basis. Analysts predict that BioNTech SE will post -2.8 earnings per share for the current year.

Analysts Set New Price Targets

Several brokerages have recently issued reports on BNTX. Hsbc Global Res raised BioNTech from a “hold” rating to a “strong-buy” rating in a report on Friday, August 2nd. HSBC upgraded BioNTech from a “hold” rating to a “buy” rating in a report on Friday, August 2nd. Deutsche Bank Aktiengesellschaft upgraded BioNTech from a “hold” rating to a “buy” rating and set a $95.00 price target on the stock in a report on Wednesday, August 7th. Jefferies Financial Group increased their price target on BioNTech from $90.00 to $96.00 and gave the company a “hold” rating in a report on Friday. Finally, HC Wainwright restated a “buy” rating and set a $113.00 price target on shares of BioNTech in a report on Tuesday, August 27th. One investment analyst has rated the stock with a sell rating, six have given a hold rating, five have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the stock has an average rating of “Hold” and an average price target of $108.00.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.